Skip to main content

Together we are beating cancer

Donate now

Cancer Research Matters - series 1

A podcast from Cancer Research UK that features some of the incredible researchers behind cancer research.
We’ll provoke conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.

The first series focusses on the 20th anniversary of Cancer Research UK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.

Showing 9 out of 9 results

In this episode I tease out four themes that emerged over this first series that give some interesting insights into how we work as scientists, research leaders and research translators. It features some of the fantastic researchers that we have interviewed over the past year – including Professor Steve Jackson, Professor Ruth Plummer, Dr Simon Boulton, Professor Sir Leszek Borysiewicz, Professor Karen Vousden, Professor Richard Gilbertson and Professor Charles Swanton. In this episode I tease out four themes that emerged over this first series that give some interesting insights into how we work as scientists, research leaders and research translators. It features some of the fantastic researchers that we have interviewed over the past year – including Professor Steve Jackson, Professor Ruth Plummer, Dr Simon Boulton, Professor Sir Leszek Borysiewicz, Professor Karen Vousden, Professor Richard Gilbertson and Professor Charles Swanton.

by Phil Prime | Podcast | 14 February 2023

14 February 2023

This entry is part 9 of 9 in the series Cancer Research Matters - series 1

This episode features Dr Simon Boulton. Simon is a leader in the field of DNA damage sensing, repair and telomere maintenance. He talks about the dawn of the field of DNA damage repair, why an entrepreneurial approach to your research is so valuable and the importance of venture capital in the innovation landscape. This episode features Dr Simon Boulton. Simon is a leader in the field of DNA damage sensing, repair and telomere maintenance. He talks about the dawn of the field of DNA damage repair, why an entrepreneurial approach to your research is so valuable and the importance of venture capital in the innovation landscape.

by Phil Prime | Podcast | 20 January 2023

20 January 2023

This entry is part 8 of 9 in the series Cancer Research Matters - series 1

This episode features our Chief Clinician Professor Charles Swanton. He talks about lung cancer, the power of the translational mind-set and delves into the flagship project, TRACERx. This episode features our Chief Clinician Professor Charles Swanton. He talks about lung cancer, the power of the translational mind-set and delves into the flagship project, TRACERx.

by Phil Prime | Podcast | 1 November 2022

1 November 2022

This entry is part 7 of 9 in the series Cancer Research Matters - series 1

This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers. This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers.

by Phil Prime | Podcast | 6 September 2022

6 September 2022

This entry is part 6 of 9 in the series Cancer Research Matters - series 1

This episode features outgoing CRUK Chief Scientist, Professor Karen Vousden. Known for her work on the tumour suppressor protein, p53, she has also worked on HPV and cancer metabolism. She talks about the success and challenges of work around p53, her joy at being involved in the early work around HPV, the frustrations of coming so close to a huge breakthrough and how life as a researcher has changed. This episode features outgoing CRUK Chief Scientist, Professor Karen Vousden. Known for her work on the tumour suppressor protein, p53, she has also worked on HPV and cancer metabolism. She talks about the success and challenges of work around p53, her joy at being involved in the early work around HPV, the frustrations of coming so close to a huge breakthrough and how life as a researcher has changed.

by Phil Prime | Podcast | 25 August 2022

25 August 2022

This entry is part 5 of 9 in the series Cancer Research Matters - series 1

This episode features CRUK Chairman, Professor Sir Leszek Borysiewicz. Following a distinguished academic and clinical research career, Leszek’s roles have included Chief Executive of the Medical Research Council and Vice Chancellor of the University of Cambridge. He talks about the development of the HPV vaccine, the difficulties of navigating a research career and why we must start to embrace failure… even a negative result, he says, is positive. This episode features CRUK Chairman, Professor Sir Leszek Borysiewicz. Following a distinguished academic and clinical research career, Leszek’s roles have included Chief Executive of the Medical Research Council and Vice Chancellor of the University of Cambridge. He talks about the development of the HPV vaccine, the difficulties of navigating a research career and why we must start to embrace failure… even a negative result, he says, is positive.

by Phil Prime | Podcast | 20 July 2022

20 July 2022

This entry is part 4 of 9 in the series Cancer Research Matters - series 1

This episode features Professor Sara Zanivan. She talks about how understanding the tumour microenvironment has developed over the past 20 years, how the techniques of proteomics have really freed researchers to ask the important questions and why we could even see mass-spec proteomics in the clinic. This episode features Professor Sara Zanivan. She talks about how understanding the tumour microenvironment has developed over the past 20 years, how the techniques of proteomics have really freed researchers to ask the important questions and why we could even see mass-spec proteomics in the clinic.

by Phil Prime | Podcast | 23 May 2022

23 May 2022

This entry is part 3 of 9 in the series Cancer Research Matters - series 1

The episode features Steve Jackson. Steve is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research. The episode features Steve Jackson. Steve is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research.

by Phil Prime | Podcast | 23 March 2022

23 March 2022

This entry is part 2 of 9 in the series Cancer Research Matters - series 1

The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life. The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life.

by Phil Prime | Podcast | 4 February 2022

4 February 2022

This entry is part 1 of 9 in the series Cancer Research Matters - series 1